Volume 29, Number 8—August 2023
Dispatch
Multidrug-Resistant Shigella sonnei Bacteremia among Persons Experiencing Homelessness, Vancouver, British Columbia, Canada
A. Stefanovic
, N. Matic, G. Ritchie, C.F. Lowe, V. Leung, M. Hull, M. Alam, M. Dawar, S. Champagne, and M.G. Romney
, N. Matic, G. Ritchie, C.F. Lowe, V. Leung, M. Hull, M. Alam, M. Dawar, S. Champagne, and M.G. Romney
Table
Characteristics and outcomes of cases of Shigella sonnei bacteremia during recent and historical time periods, Vancouver, British Columbia, Canada*
| Characteristic | Cases of Shigella sonnei bacteremia |
|
|---|---|---|
| Recent, 2021–Jan 2023, n = 9 | Historical, 2010–2020, n = 2 | |
| Age, y |
Median 45, range 27–69 |
Median 62, range 56–68 |
| Sex |
8 (89%) male |
2 (100%) male |
| Housing | ||
| Private residence | 1 (11) | 2 (100) |
| Single room occupancy hotel/shelter | 5 (56) | 0 |
| No fixed address | 2 (22) | 0 |
| Rehabilitation center |
1 (11) |
0 |
| Men who have sex with men |
0 |
2 (100) |
| Travel history |
0 |
1 (50) |
| Substance use |
8 (89) |
0 |
| Coexisting conditions | ||
| HIV | 1 (11) | 1 (50) |
| Immunocompromising conditions† | 1 (11) | 1 (50) |
| Liver disease | 2 (22) | 0 |
| Pulmonary disease | 1 (11) | 0 |
| Cardiac disease | 1 (11) | 0 |
| Chronic renal disease |
0 |
1 (50) |
| Recurrence |
1 (11) |
0 |
| Hospitalization | ||
| Admitted to hospital ward | 6 (67) | 2 (100) |
| Declined hospital admission |
3 (33) |
0 |
| Antimicrobial test results | ||
| Ampicillin resistant | 9 (100) | 2 (100) |
| Trimethoprim/sulfamethoxazole resistant | 9 (100) | 2 (100) |
| Ciprofloxacin resistant | 9 (100) | 0 |
| Azithromycin resistant | 8 (89) | Not tested |
| Ceftriaxone resistant |
1 (11) |
0 |
| Treatment | ||
| 7–14 d of effective oral antimicrobial agent | 0 | 1 (50) |
| 7–14 d of effective IV antimicrobial agent | 6 (67) | 1 (50) |
| Incomplete | 3 (33) | 0 |
| 30-d all-cause mortality | 0 | 0 |
*Values are no. (%) except as indicated. IV, intravenous. †Organ transplantation, malignancy receiving chemotherapy, asplenia, uncontrolled HIV (CD4 count <200 cells/μL), and immunosuppressive medications.
Page created: June 02, 2023
Page updated: July 20, 2023
Page reviewed: July 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.